GW Pharmaceuticals Regains Commercialization Rights to Sativex

March 4, 2020
Pharmaceutical Technology Editors

GW Pharmaceuticals and Bayer have revealed that GW will regain the exclusive commercialization rights for Sativex (delta-9-tetrahydrocannabinol [THC] and cannabidiol [CBD]) in the UK.

GW Pharmaceuticals and Bayer have revealed, in a March 2, 2020 press release, that GW will regain the exclusive commercialization rights for Sativex (delta-9-tetrahydrocannabinol [THC] and cannabidiol [CBD]) in the United Kingdom.

Under the terms of the agreement, a transitional period will be in place until Dec. 31, 2020, after which point, GW will assume all responsibilities for Sativex (known by the USAN name nabiximols) in the UK. Since the approval of Sativex, Bayer has been responsible for all marketing in the country.

During the transition period, the companies will work together closely to ensure a seamless changeover for healthcare professionals and patients. There is no change to the day-to-day business practices for now, and stakeholders will receive further notification when transfers and operations are anticipated.

Source: GW Pharmaceuticals